Simeprevir in combination with pegylated interferon-α and ribavirin in the treatment of naïve patients with genotype 1 chronic hepatitis C

Full Text

Abstract

Triple therapy with pegylated interferon-α, ribavirin, and simeprevir is now optimal among the antiviral treatment options available in the Russian Federation for patients with chronic hepatitis C (CHC), including in the compensated stage of liver cirrhosis. The optimality of this combination is determined by its high efficacy - the given combination of antiviral agents allows one to predict that more than 90% of naïve patients with CHC will achieve a sustained virological response as 97-99% of the Russian population patients is infected with hepatitis C virus subgenotype 1b. The second important aspect that can recognize the triple therapy incorporating simeprevir to be most rational now is its safety similar to that of double therapy with pegylated interferon-α and ribavirin. In addition, the absolute advantages of the triple therapy including simeprevir are shorter treatment duration (for a total of 24 weeks) for all naïve patients with CHC, including those in the compensated stage of cirrhosis, and simeprevir taken as one capsule once daily.

Full Text

Симепревир в комбинации с пегилированным интер­фероном α и рибавирином в лечении первичных больных хроническим гепатитом С, инфицированных вирусом гепатита С 1-го генотипа. - Аннотация. В настоящее время среди доступных в Российской Федерации вариантов противовирусной терапии у больных хроническим гепатитом С (ХГС), в том числе на стадии компенсированного цирроза печени, оптимальной является трехкомпонентная терапия пегилированным интерфероном α, рибавирином и симепревиром. Оптимальность данной комбинации определяется ее высокой эффективностью - указанная комбинация противовирусных средств позволяет рассчитывать на достижение стойкого вирусологического ответа у более 90% первичных больных ХГС, так как 97-99% российской популяции больных инфицированы вирусом гепатита С субгенотипа 1b. Вторым важным аспектом, позволяющим признать трехкомпонентную терапию с симепревиром наиболее рациональной в настоящее время, является ее безопасность, сопоставимая с безопасностью двухкомпонентной терапии пегилированным интерфероном α и рибавирином. Кроме того, безусловными преимуществами трехкомпонентной терапии с симепревиром являются сокращение длительности лечения до 24 нед суммарно для всех первичных больных ХГС, включая больных на стадии компенсированного цирроза печени, и однократный прием симепревира в виде одной капсулы в сутки.
×

About the authors

É Z Burnevich

Email: eduard.z.burnevich@gmail.com

References

  1. Global Alert and Response (GAR). Hepatitis C. Доступно на: www.who.int
  2. Гордовская Н.Б., Козловская Л.В., Милованова С.Ю. и др. Криоглобулинемический васкулит с поражением почек, ассоциированный с вирусом гепатита С: современные возможности лечения. Тер арх 2013; 6, 78-84.
  3. Mohd H.K., Groeger J., Flaxman A.D., Wiersma S.T. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57 (4): 1333-1342.
  4. Hope V.D., Eramova I., Capurro D., Donoghoe M.C. Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiol Infect 2014; 142 (2): 270-286.
  5. www.fcgsen.ru
  6. Te H.S., Jensen D.M. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010; 14 (1): 1-21.
  7. Negro F., Alberti A. The global health burden of hepatitis C virus infection. Liver Int 2011; 31 Suppl 2: 1-3.
  8. cf16.hc.ru/~rcvhru/
  9. Jesudian A.B., de Jong Y.P., Jacobson I.M. Emerging therapeutic targets for hepatitis C virus infection. Clin Gastroenterol Hepatol 2013; 11 (6): 612-619.
  10. EASL Clinical Practice Guidelines, management of hepatitis C virus infection. European Association for Study of Liver. J Hepatol 2014; 60 (2): 392-420.
  11. Recommendations for Testing, Managing, and Treating Hepatitis C. Доступно на: www.hcvguidelines.org/full-report/introduction
  12. van der Meer A.J., Veldt B.J., Feld J.J. et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308 (24): 2584-2593.
  13. Deuffic-Burban S., Deltenre P., Buti M. et al. Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology 2012; 143 (4): 974-985.
  14. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55 (2): 245-264.
  15. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B.; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49 (4): 1335-1374.
  16. Thomas R.M., Brems J.J., Guzman-Hartman G. et al. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003; 9 (9): 905-915.
  17. Mutimer D.J., Lok A. Management of HBV- and HCV-induced end stage liver disease. Gut 2012; 61 Suppl 1: i59-67.
  18. Everson G.T., Trotter J., Forman L. et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42 (2): 255-262.
  19. Ghany M.G., Nelson D.R., Strader D.B. et al. Genotype 1 HCV treatment guidelines. Hepatology 2011; 54: 1433-1444.
  20. Sherman K.E., Flamm S.L., Afdhal N.H. et al.; ILLUMINATE Study Team. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365 (11): 1014-1024.
  21. McHutchison J.G., Everson G.T., Gordon S.C. et al.; PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360 (18): 1827-1838.
  22. Hézode C., Forestier N., Dusheiko G. et al.; PROVE2 Study Team. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360 (18): 1839-1850.
  23. Jacobson I.M., McHutchison J.G., Dusheiko G. et al.; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364 (25): 2405-2416.
  24. Kwo P.Y., Lawitz E.J., McCone J. et al.; SPRINT-1 investigators. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376 (9742): 705-716.
  25. Poordad F., McCone J. Jr, Bacon B.R. et al.; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364 (13): 1195-1206.
  26. Nelson D.R., Poordad F., Feld J.J. et al., on behalf of the CONCISE Study Team. High SVR rates (SVR4) for 12-week total telaprevir combination therapy in IL28B CC treatment-naives and prior relapsers with G1 chronic hepatitis C: Concise interim analyses. 48th Annual Meeting of the European Association for the Study of the Liver, April 24-28, 2013, Amsterdam, Netherlands; abstract 881.
  27. Абдурахманов Д.Т., Морозов В.Г., Никитин И.Г. и др. Безопасность и эффективность телапревира в лечении хронического гепатита С у больных российской популяции, включенных в исследование по программе раннего доступа. Рос журн гепатол, гастроэнтерол, колопроктол 2014; 1: 39-46.
  28. Hézode C., Fontaine H., Dorival C. et al.; CUPIC Study Group. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 2013; 59 (3): 434-441.
  29. Lin T.I., Lenz O., Fanning G. et al. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother 2009; 53 (4): 1377-1385.
  30. Reesink H., Verloes R., Farha K.A. Safety of the HCV protease inhibitor TMC435350 in healthy volunteers and safety and activity in chronic hepatitis C infected individuals: a phase I study. EASL, 2008, Milan, Italy, A. 64.
  31. Simmen K., Verloes R., Abou Farha K. Results of a phase I placebo-controlled trial in healthy volunteers to examine the safety, tolerability, and pharmacokinetics of the HCV protease inhibitor TMC435350 after single and repeated dosing. AASLD, 2007, Boston, A. 1318.
  32. Tsantrizos Y.S. TMC-435, an NS3/4A protease inhibitor for the treatment of HCV infection. Curr Opin Investig Drugs 2009; 10 (8): 871-881.
  33. Huisman M.T., Snoeys J., Monbaliu J. In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters. AASLD, 2010, Boston, A. 278.
  34. Kiser J.J., Burton J.R. Jr., Everson G.T. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2013; 10 (10): 596-606.
  35. Reesink H.W., Fanning G.C., Farha K.A. et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology 2010; 138 (3): 913-921.
  36. Hayashi N., Seto C., Kato M. et al. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol 2014; 49 (1): 138-147.
  37. Cummings M.D., Lindberg J., Lin T.I. et al. Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease target. Angew Chem Int Ed Engl 2010; 49 (9): 1652-1655.
  38. Jacobson I.M., Dore G.J., Foster G.R. et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomized, double-blind, placebo-controlled trial. Lancet 2014; 384 (9941): 403-413.
  39. Jacobson I.M., Dore G.J., Foster G.R. et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014; 384 (9941): 403-413.
  40. Xue W., Pan D., Yang Y. et al. Molecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K, A156V and D168A to TMC435. Antiviral Res 2012; 93 (1): 126-137.
  41. Maekawa S., Enomoto N. Once-daily simeprevir in combination with pegylated-interferon and ribavirin: a new horizon in the era of direct-acting antiviral agent therapy for chronic hepatitis C. J Gastroenterol 2014; 49 (1): 163-164.
  42. Talwani R., Heil E.L., Gilliam B.L., Temesgen Z. Simeprevir: a macrocyclic HCV protease inhibitor. Drugs Today (Barc) 2013; 49 (12): 769-779.
  43. Vaidya A., Perry C.M. Simeprevir: first global approval. Drugs 2013; 73 (18): 2093-2106.
  44. You D.M., Pockros P.J. Simeprevir for the treatment of chronic hepatitis C. Expert Opin Pharmacother 2013; 14 (18): 2581-2589.

Statistics

Views

Abstract: 236

Article Metrics

Metrics Loading ...

Refbacks

  • There are currently no refbacks.

Copyright (c) 2014 Burnevich É.Z.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies